Role of interleukin-1 inhibitors in the management of gout

Pharmacotherapy

Volumn 33, Issue 7, 2013, Pages 744-753

  Tran, Tran H ^a   Pham, Jacqueline T ^b   Shafeeq, Hira ^a   Manigault, Kendra R ^c   Arya, Vibhuti ^a  

^a ST JOHN'S UNIVERSITY   (United States)

^b Kaiser Permanente of Georgia ^*  (United States)

^c MERCER UNIVERSITY   (United States)

Author keywords

Anakinra; Canakinumab; Gout; Interleukin 1 inhibitors; Interleukin 1 receptor antagonists; Rilonacept

Indexed keywords

ALLOPURINOL; CANAKINUMAB; COLCHICINE; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; GLUCOCORTICOID; INTERLEUKIN 1; METHYLPREDNISOLONE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PREDNISOLONE; PREDNISONE; PROBENECID; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT; TRIAMCINOLONE ACETONIDE;

ABSCESS; ABSENCE OF SIDE EFFECTS; ACUTE DISEASE; BLEEDING; CARDIOPULMONARY INSUFFICIENCY; CHRONIC DISEASE; CHRONIC KIDNEY FAILURE; CINCA SYNDROME; CLINICAL EFFECTIVENESS; DISEASE EXACERBATION; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELEVATED BLOOD PRESSURE; FAMILIAL COLD AUTOINFLAMMATORY SYNDROME; GASTROENTERITIS; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; GOUT; HEART ARRHYTHMIA; HEART MUSCLE ISCHEMIA; HUMAN; INFECTION; INJECTION SITE REACTION; KIDNEY ARTERY STENOSIS; KIDNEY DYSFUNCTION; LOADING DRUG DOSE; LOW DRUG DOSE; MALIGNANT NEOPLASTIC DISEASE; MEDICATION COMPLIANCE; MUCKLE WELLS SYNDROME; NEUTROPENIA; NONHUMAN; PATIENT COMPLIANCE; PNEUMONIA; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SINGLE DRUG DOSE; SYSTEMIC THERAPY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION;

ANAKINRA; CANAKINUMAB; GOUT; INTERLEUKIN-1 INHIBITORS; INTERLEUKIN-1 RECEPTOR ANTAGONISTS; RILONACEPT;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; GOUT; GOUT SUPPRESSANTS; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1; RECOMBINANT FUSION PROTEINS;

EID: 84885401730     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1002/phar.1265     Document Type: Review

References (48)

1. Dalbeth N, Lindsay K. The patient's experience of gout: new insights to optimize management. Curr Rheumatol Rep 2012;14:173-8.
2. Andersson GBJ, Bouchard JE, Bozic KJ, et al. Arthritis and related conditions. United States Bone and Joint Decade. In: The burden of musculoskeletal diseases in the United States. Rosemont, IL: American Academy of Orthopedic Surgeons, 2008:75-102.
3. Saseen JJ, Agashivala N, Allen RR, Ghushchyan V, Yadao AM, Nair KV. Comparison of patient characteristics and goutrelated health-care resource utilization and costs in patients with frequent versus infrequent gouty arthritis attacks. Rheumatology 2012;51:2004-12.
4. Smith L. Savient Pharmaceuticals: Thoughts on the Chronic Refractory Gout Market. Available from http://seekingalpha. com/article/312182-savient- pharmaceuticals-thoughts-on-thechronic- refractory-gout-market. Accessed October 1, 2012.
5. Burns CM, Wortmann RL. Gout therapeutics: new drugs for an old disease. Lancet 2011;377:165-77.
6. So A, De Smedt T, Revaz S, Tschopp J. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 2007;9:R28.
7. Neogi T. IL-1 antagonism in acute gout: is targeting a single cytokine the answer? Arthritis Rheum 2010;62:2845-9.
8. Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006;65:1312-24.
9. Jordan KM, Cameron JS, Snaith M, et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology 2007;46(8):1372-4.
10. Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yu TF. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 1977;20:896-900.
11. Kavousi M, Elias-Smale S, Rutten JHW, et al. Evaluation of newer risk markers for coronary heart disease risk classification. Ann Intern Med 2012;156:438-44.
12. Neogi T, Hunter DJ, Chaisson CE, Allensworth-Davies D, Zhang YQ. Frequency and predictors of inappropriate management of recurrent gout attacks in a longitudinal study. J Rheumatol 2006;33:104-9.
13. Khanna D, Khanna PP, Fitzgerald JD, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and anti-inflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res 2012;64:1447-61.
14. Schumacher HR, Berger MF, Li-Yu J, et al. Efficacy and tolerability of celecoxib in the treatment of acute gouty arthritis: a randomized controlled trial. J Rheumatol 2012;39:1859-66.
15. Takeda Pharmaceuticals. Colcys (colchicines) package insert. Deerfield, IL; 2012.
16. Schlesinger N. Management of acute and chronic gouty arthritis: present state-of-the-art. Drugs 2004;64(21):2399-416.
17. Schlesinger N, Mysler E, Lin HY, et al. Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomized study. Ann Rheum Dis 2011;70:1264-71.
18. Rider TG, Jordan KM. The modern management of gout. Rheumatology 2010;49:5-14.
19. Regeneron Pharmaceuticals, Inc. Arcalyst (rilonacept). Tarrytown, NY; 2008.
20. Tran AP, Edelman J. Interleukin-1 inhibition by anakinra in refractory chronic tophaceous gout. Int J Rheum Dis 2011;14: e33-7.
21. Dinarello CA. Blocking interleukin-1b in acute and chronic autoinflammatory diseases. J Intern Med 2011;269:16-28.
22. Sundy JS. Progress in the pharmacotherapy of gout. Curr Opin Rheumatol 2010;22:188-93.
23. So A, Busso N. Magic bullet for gout? Ann Rheum Dis 2009;68:1517-9.
24. Di Giovine FS, Malawista SE, Nuki G, Duff GW. Interleukin 1 (IL 1) as a mediator of crystal arthritis. Stimulation of T cell and synovial fibroblast mitogenesis by urate crystal-induced IL-l. J lmmunol 1987;138:3213-8.
25. McGonagle D, Tan AL, Shankaranarayana S, Madden S, Emery P, McDermott MF. Management of treatment resistant inflammation of acute on chronic tophaceous gout with anakinra. Ann Rheum Dis 2007;66:1683-4.
26. Amgen. Kineret (anakinra) package insert. Thousand Oaks, CA; 2001-2003.
27. Facts and Comparisons. Available from http://online.factsandcomparisons. com/MonoDisp.aspx?monoID=fandc-hcp13757&quick=184075%7c5&search= 184075%7c5&isstemmed=True#firstMatch. Accessed July 26, 2012.
28. Gratton SB, Scalapino KJ, Fye KH. Case of anakinra as a steroid-sparing agent for gout inflammation. Arthritis Rheum 2009;61(9):1268-70.
29. Nocturne G, Ora J, Ea HK, Liote F. Influenza A H1N1 and anakinra exposure in a patient with gout. Joint Bone Spine. 2010;77:369-70.
30. Chen K, Fields T, Mancuso CA, Bass AR, Vasanth L. Anakinra's efficacy is variable in refractory gout: report of ten cases. Semin Arthritis Rheum 2010;40:210-4.
31. Alten R, Gram H, Joosten LA, et al. The human anti-IL-1b antibody ACZ885 is effective in joint inflammation models in mice and in proof-of-concept study in patients with rheumatoid arthritis. Arthritis Res Ther 2008;10:R67.
32. Martinon F, Petrilli V, Mayor A, et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006;440:237-41.
33. Lachmann HJ, Kone-Paut I, Keummerle-Deschener JB, et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 2009;360:2416-25.
34. Novartis Pharmaceuticals Corporation. Ilaris (canakinumab) package insert. New Jersey: East Hanover, 2012.
35. So A, De Meulemeester M, Pikhlak A, et al. Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: results of a multicenter, phase II, dose-ranging study. Arthritis Rheum 2010;62:3064-76.
36. Schlesinger N, Alten R, Bardin T, et al. Canakinumab for acute gouty arthritis in patients with limited treatment options: results fromtwo randomized,multicentre, active-controlled, double-blind trials and their extensions. Ann RheumDis 2012;71:1839-48.
37. Arthritis Advisory Committee Meeting June 21, 2011. Available from http://www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/ Drugs/ArthritisAdvisoryCommittee/ UCM259596.pdf. Accessed July 27, 2012.
38. Schumacher HR Jr, Sundry JS, Terkeltaub R, et al. Rilonacept (interleukin-1 trap) in the prevention of acute gout flares during initiation of urate-lowering therapy. Arthritis Rheum 2012;64:876-84.
39. Terkeltaub R, Sundy JS, Schumacher HR, et al. The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomized, single-blind pilot study. Ann Rheum Dis 2009;68:1613-7.
40. Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res 2012;64:1431-46.
41. Schumacher HR Jr, Evans RR, Saag KG, et al. Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study. Arthritis Care Res 2012;64:1462-70.
42. Arthritis Advisory Committee Meeting May 8, 2012. Available from http://www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/ Drugs/ArthritisAdvisoryCommittee/ UCM313312.pdf. Assessed October 1, 2012.
43. Park H, Rascati KL, Prasla K, McBayne T. Evaluation of health care costs and utilization patterns for patients with gout. Clin Ther 2012;34:640-52.
44. Wertheimer AI, Davis MW, Lauterio TJ. A new perspective on the pharmacoeconomics of colchicine. Curr Med Res Opin 2011;27:931-7.
45. Sarawate CA, Brewer KK, Yang W, et al. Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin Proc 2006;81:925-34.
46. Reach G. Treatment adherence in patients with gout. Joint Bone Spine 2011;78:456-9.
47. Harrold LR, Mazor KM, Velten SJ, Ockene IS, Yood RA. Patients and providers view gout differently: a qualitative study. Chronic Illness 2010;6:263-71.
48. Red Book (July 2008 update). Montvale, NJ: Thomson PDR, 2008:43(7).